FGF23, Hypophosphatemia, and Emerging Treatments
ABSTRACT FGF23 is an important hormonal regulator of phosphate homeostasis. Together with its co‐receptor Klotho, it modulates phosphate reabsorption and both 1α‐hydroxylation and 24‐hydroxylation in the renal proximal tubules. The most common FGF23‐mediated hypophosphatemia is X‐linked hypophosphat...
Main Authors: | Erik A Imel, Andrew Biggin, Aaron Schindeler, Craig F Munns |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-08-01
|
Series: | JBMR Plus |
Subjects: | |
Online Access: | https://doi.org/10.1002/jbm4.10190 |
Similar Items
-
Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children
by: Aaron Schindeler, et al.
Published: (2020-05-01) -
Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia
by: Silvia Martín Ramos, et al.
Published: (2020-02-01) -
FGF23 and its role in X-linked hypophosphatemia-related morbidity
by: Signe Sparre Beck-Nielsen, et al.
Published: (2019-02-01) -
Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium
by: Michaël R. Laurent, et al.
Published: (2021-03-01) -
Corrigendum: Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium
by: Michaël R. Laurent, et al.
Published: (2021-05-01)